American Gene Technologies®

In The News

Try these: Jeff GalvinHIVAmerican Gene TechnologiesPhenylketonuria

The National Institutes of Health mourns the loss of Roscoe Brady, M.D., who was AGT's Chief Scientific Officer

National Institutes of Health: “Dr Roscoe Brady & Gaucher Disease”

Jun 13, 2016

It is with great sadness that we share the news of the passing of former National Institutes of Health scientist and American Gene Chief Scientific Advisor, Roscoe O. Brady, M.D., a pioneer of modern medicine and true public servant who improved the lives of thousands…

Read More
AGT CEO Jeff Galvin talks about why cost estimates for gene therapies are wrong

Medium: “Disruption for Dummies” — Why Gene Therapy Cost Estimates are Wrong”

Apr 28, 2016

WHY GENE THERAPY COST ESTIMATES ARE WRONG – AN OP-ED FROM AGT CEO, JEFF GALVIN Last week, a colleague and I hosted our first ever Reddit AMA and were intrigued with a question posed by one /u/marefo.  So much so that I felt compelled to dive headfirst into…

Read More
American Gene CEO Jeff Galvin was quoted in a Wired article

Wired: “Obama’s Anti-Cancer Moonshot Will Need More Than Research”

Jan 13, 2016

On January 13, 2016, American Gene CEO, Jeff Galvin was asked to weigh in on Vice President Biden’s “moonshot to cure cancer”.

Read More
American Gene Technologies received an NIH Grant of $230,000 to further its Familial Dysautonomia (FD) research in 2015

National Institutes of Health: “AGT Receives NIH Grant for FD Research”

Aug 10, 2015

NIH Grant to further Familial Dysautonomia (FD) Research ROCKVILLE, Maryland. (August 10, 2015) – American Gene Technologies International, Inc. (AGT) today announced its receipt of an NIH Grant of $230,000 to further its Familial Dysautonomia (FD) research in 2015. Get the details below: NIH Grant Details

Read More
CBS news interviews AGT CEO Jeff Galvin

CBS: “Baltimore Biotech CEO Continues His Education In Order To Accomplish His Life Mission”

Jan 6, 2014

Anyone who has experienced the death of a loved one from a terrible illness can appreciate the life mission of Mr. Jeff Galvin, CEO of American Gene Technologies (AGT). Armed with a bachelor’s degree in Economics from Harvard University, Jeff and AGT work to develop…

Read More

Subscribe to News Releases and News Updates

Subscribe to our news release and published article updates to be notified when we release new content!

Follow AGT on Social Media

AGT on Facebook

Tune in to Cell & Gene: The Podcast and hear Addimmune's Dr. Marcus Conant, a pioneer in HIV research, discuss our innovative cell therapy for HIV. He shares his vision for empowering patients and transforming HIV treatment. loom.ly/96TZ0jU#HIV #celltherapy #biotech ... See MoreSee Less
View on Facebook
M&A has been steady in 2024. We count 47 private & public deals to date totaling $53 billion. 15 have been >$1 billion with cancer, rare disease & cell therapies some of the areas of interest. ... See MoreSee Less
View on Facebook
AGT CEO, Jeff Galvin, had a chat with social media influencer and HIV advocate, Raif Derrazi, to discuss the latest updates on our AGT103-T clinical trials. Dive into the conversation as they shed light on the research and what lies ahead in our mission to find a cure for HIV! loom.ly/jAThqIU#HIV #hivcure #HIVresearch #clinicaltrials ... See MoreSee Less
View on Facebook
Can genetic evidence make drugs more effective? A new study in Nature suggests YES. Drug mechanisms with genetic support have a 2.6x higher chance of success. loom.ly/NxSxjXk#genetics #science #Healthcare ... See MoreSee Less
View on Facebook